Eli Lilly to double Mounjaro production
Analysts have returned from a visit to the drugmaker’s Indianapolis headquarters, reporting that Lilly is facing a number of headwinds, one of which will be warded off by doubling the firm’s production capacity for Mounjaro.
by ulrich quistgaard, translated by daniel pedersen
In an attempt to mitigate future financial challenges, Eli Lilly will double the production of its newest and highly sought-after type 2 diabetes drug, Mounjaro, reports industry media Endpoints News.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg)
.jpg&w=384&q=75)
